Cartesian Therapeutics, Inc. (RNAC) Q2 Earnings and Revenues Top Estimates

Cartesian Therapeutics, Inc. (RNAC) came out with quarterly earnings of $0.54 per share, beating the Zacks Consensus Estimate of a loss of$ 0.81 per share. This compares to loss of $2.10 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of 166.67%. A quarter ago, it was expected that this company would post a loss of$ 0.81 per share when it actually produced a loss of $1.97, delivering a surprise of -143.21%. Over the last four qu ...